Raymond James Initiates Coverage On Nektar Therapeutics with Market Perform Rating

Benzinga · 3d ago
Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Market Perform rating.